



**Patient:** Test Patient  
**DOB:** 01-01-1944  
**Gender:** Female

**Accession:** 123456  
**Specimen:** Urine  
**Provider:** Test Provider

**Client:** Test Client  
**Collected Date:** 01-03-2023  
**Report Date:** 01-07-2023

## Urine Culture Panel FINAL RESULT

### Enterococcus faecalis

01-07-2023 02:47 PM >100,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Ampicillin	0.5	S
Ciprofloxacin	>2	R
Daptomycin	≤0.5	S
Gentamicin 500 ug/ml	>500	R
Levofloxacin	>4	R
Linezolid	≤1	S
Nitrofurantoin	≤32	S
Penicillin	2	S
Streptomycin 1000 ug/ml	≤1000	S
Tetracycline	>16	R
Vancomycin	1	S

### Escherichia coli

01-06-2023 02:24 PM >100,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Amikacin	≤8	S
Ampicillin	>16	R
Ampicillin/Sulbactam	≤4	S
Cefazolin	>16	R
Cefepime	≤2	S
Ceftolozane/Tazobactam 4	≤2	S
Ceftriaxone	32	R
Ciprofloxacin	>2	R
Doripenem	≤0.5	S
Ertapenem	≤0.25	S
Gentamicin	≤2	S
Imipenem	≤1	S
Levofloxacin	>8	R
Meropenem	≤0.5	S
Piperacillin/Tazobactam	≤8	S
Tobramycin	≤2	S
Trimethoprim/Sulfamethoxazole	>4	R

R = RESISTANT

S = SENSITIVE

I = INTERMEDIATE

NI = NO INTERPRETATION

SD = Susceptible Dose Dependent

## THE HUMAN ADVANTAGE

IN LABORATORY TESTING

Accession #123456

Patient Test Patient

DOB 01-01-1944

Urine Culture Panel

FINAL RESULT

Page 1 of 2



### Providencia stuartii

01-06-2023 02:24 PM >100,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Amikacin	≤8	S
Ampicillin	>16	R
Ampicillin/Sulbactam	16	I
Cefazolin	8	R
Cefepime	≤2	S
Ceftolozane/Tazobactam 4	≤2	S
Ceftriaxone	≤0.5	S
Ciprofloxacin	>2	R
Doripenem	≤0.5	S
Ertapenem	≤0.25	S
Imipenem	≤1	S
Levofloxacin	8	R
Meropenem	≤0.5	S
Piperacillin/Tazobactam	≤8	S
Trimethoprim/Sulfamethoxazole	≤2	S

R = RESISTANT

S = SENSITIVE

I = INTERMEDIATE

NI = NO INTERPRETATION

SD = Susceptible Dose Dependent

## THE HUMAN ADVANTAGE

IN LABORATORY TESTING

Accession #123456

Patient Test Patient DOB 01-01-1944

Urine Culture Panel FINAL RESULT

Page 2 of 2